Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms

Harumi Okuyama1, Peter H Langsjoen2, Tomohito Hamazaki3, Yoichi Ogushi4, Rokuro Hama5, Tetsuyuki Kobayashi6 and Hajime Uchino7

1Nagoya City University and Institute for Consumer Science and Human Life, Kinjo Gakuin University, 2-1722 Omori, Moriya, Nagoya 463-8521, Japan
2Clinical Cardiology Practice, 1107 Doctors Drive, Tyler, TX 75701, USA
3Toyama Onsen Daini Hospital, 1-13-6 Tarumari-Nishimachi, Toyama-city, Toyama 939-8271, Japan
4Ogushi Institute of Medical Informatics, 12-43-2, Daikancho, Hirasuka, Kanagawa 254-0807, Japan
5Non-Profit Organization Japan Institute of Pharmacovigilance (Kusuri-no-Check), Ueshio 5-1-20, Tennouji-ku, Osaka 543-0002, Japan
6Graduate School of Humanities and Sciences, Ochanomizu University, 2-1-1 Ohtsuka, Bunkyo-ku, Tokyo 112-8610, Japan
7Medical Corp. Uchino-kaï, 5-10-12 Yahata, Minami-ku, Kumamoto 861-4113, Japan

*Author for correspondence:
Tel.: +81 528 763 840
Fax: +81 528 763 840
okuyamah@kinjo-u.ac.jp

In contrast to the current belief that cholesterol reduction with statins decreases atherosclerosis, we present a perspective that statins may be causative in coronary artery calcification and can function as mitochondrial toxins that impair muscle function in the heart and blood vessels through the depletion of coenzyme Q10 and ‘heme A’, and thereby ATP generation. Statins inhibit the synthesis of vitamin K2, the cofactor for matrix Gla-protein activation, which in turn protects arteries from calcification. Statins inhibit the biosynthesis of selenium containing proteins, one of which is glutathione peroxidase serving to suppress peroxidative stress. An impairment of selenoprotein biosynthesis may be a factor in congestive heart failure, reminiscent of the dilated cardiomyopathies seen with selenium deficiency. Thus, the epidemic of heart failure and atherosclerosis that plagues the modern world may paradoxically be aggravated by the pervasive use of statin drugs. We propose that current statin treatment guidelines be critically reevaluated.

The relationship between plasma total cholesterol (TC) and coronary heart disease (CHD) is not simple. Around 1990, the ‘bad low-density lipoprotein cholesterol (LDL-C), good high-density lipoprotein cholesterol (HDL-C) hypothesis’ was introduced in clinical trials. Because the direct assay method to determine LDL-C was found to be unreliable, LDL-C values are presently calculated by the Friedewald’s equation, LDL-C = TC−HDL-C−0.2 × triglyceride (TG; in units of mg/dl), but the equation is not accurate when the HDL-C and TG values are extremely high. There are cases when the formula ‘LDL-C = TC−80’ mg/dl is used. We will use TC and LDL-C without any further comments, and the latter comprises roughly two-thirds of the former.

The ‘bad & good cholesterol hypothesis’ lost its foundation

The ‘good and bad cholesterol hypothesis’ is based on simplified interpretations that LDL carries TGs and cholesterol to peripheral tissues, whereas HDL reverse-transport cholesterol to the liver to excrete excess cholesterol to feces, mostly as bile acids. However, HDL contains lecithin cholesterol acyltransferase enzyme to form cholesterol ester, which is transported to LDL by cholesterol ester transport protein in plasma. Roughly 1.5 g of cholesterol is required daily in adults for a variety of essential functions, and 0.3 g (about half of ingested cholesterol) can be obtained from 2 eggs plus 100 g meat and the rest (~1.2 g), the majority of daily required amount, is biosynthesized in adult tissues. The cholesterol taken-up by HDL is transferred to LDL, which is redistributed to and reused by peripheral tissues.

Recently, cholesterol ester transport protein inhibitors were developed and they were effective in lowering LDL-C/HDL-C ratios but they were essentially ineffective in preventing CHD [1]. Moreover, statins or statins plus other cholesterol-lowering drugs were effective in lowering LDL-C but were essentially ineffective in preventing CHD [2,3] as will be summarized below. All these observations go against the ‘good cholesterol/bad cholesterol hypothesis’.
and we should not try to explain the correlation between plasma cholesterol levels and CHD events based on this hypothesis.

Since the introduction of statins to clinical medicine in 1987, several kinds of statins were reported to be effective in lowering LDL-C and also preventing CHD events (mostly in 1990s). However, unfair and unethical problems were associated with clinical trials reported by industry-supported scientists, and new penal regulations on clinical trials came into effect in 2004 [4,5]. After 2004–2005, all clinical trials, performed by scientists relatively free of conflict of interest with pharmaceutical industries, reported that statins were effective in lowering LDL-C but no significant beneficial effects were observed for the prevention of CHD (FIGURE 1). Currently, the majority of scientists continue to claim that statins are effective in preventing CHD, but these claims are based on meta-analyses of reports, including those published before the EU regulation (mostly in 1990s). However, our group did not adopt the results of industry-supported publications as reliable in our cholesterol guidelines [6,7]. Thus, we are in a position not to accept the effectiveness of statins to prevent CHD (FIGURE 1, left), but rather we support the pharmacological interpretations that statins stimulate the development of atherosclerosis and heart failure. The lines of evidence described below led us to propose that current statin therapy should be critically and urgently reevaluated.

**Statins are mitochondrion toxic**

In mitochondria, subcellular organelles, electron transport chain and ATP synthesizing enzymes are localized in the inner membranes (FIGURE 2). Fatty acids and sugars are burned (hydrogen is pulled out) to store energy as ATP. In the electron transport chain, each hydrogen (H) atom forms an electron (e^-) and a proton (H+), and the electron is transported through complex I or complex II to coenzyme Q_{10} (CoQ_{10}) and then to complex III and finally to complex IV. Protons are concentrated in the mitochondrial membrane space between the outer and the inner membranes and they form a gradient that drives the ATP-synthesizing enzyme ATPase, and the molecular motor is turned on to generate ATP [8,9].

CoQ_{10} (both in its oxidized ubiquinone and reduced ubiquinol forms) and ‘heme A’ are essential components of the electron transport chain and are synthesized from prenyl-intermediates in

---

**Figure 1. Clinical trials of statins for the prevention of CHD-comparison of the effectiveness reported before and after the year 2004 when new penal regulations on clinical trials came into effect in the EU.** The arrow tail and head represent the LDL-C level and CHD event of the control and intervention groups, respectively. The major types of the participants are shown in parentheses. Each clinical trial with statin is shown in abbreviated name. CHD: Coronary heart disease; CRP: C-reactive protein; DM: Diabetes mellitus; FH: Familial hypercholesterolemia; LDL-C: Low-density lipoprotein cholesterol.

Modified with permission from Lipid Technology [7].

doi: 10.1586/17512433.2015.1011125
the cholesterol biosynthetic pathway. Statins inhibit CoQ10 and 'heme A' biosynthesis, and thereby ATP generation. ATP is essential for normal heart muscle function, metabolism of cellular components and other activities in cell life. Cholesterol is a major component of cell membranes, functioning to maintain their integrity, which is likely to be affected by statins. Thus, statins are mitochondrial toxins making all cells ATP depleted. Because most mammalian cells depend on mitochondria for their energy metabolism, statins are general cell toxins.

CoQ10 is an essential cofactor in electron and proton transport in mitochondrial energy production [8–10], as well as in several other aspects of cellular metabolism [11]. The bioenergetic effect of CoQ10 is believed to be of fundamental importance in its clinical application, particularly as it relates to cells with exceedingly high metabolic demands such as cardiac myocytes. The reduced form of CoQ10 (ubiquinol) is recognized to be a clinically relevant antioxidant in different cellular compartments, especially the mitochondrial membranes [12,13], where it protects mitochondrial DNA from damage. It is well known that mitochondrial DNA is much more vulnerable to oxidative damage than nuclear DNA.

Decreased ATP generation & resulting cell damage contribute to the development of CHD in familial hypercholesterolemia cases & in statin-treated people

The initial pathophysiology of the onset of atherosclerosis has not been well defined (Figure 3). However, any tissue damage, whether derived from a pathogen or noninfectious damage, may induce inflammation to repair damaged tissues leading to many diseases, including atherosclerosis. These inflammatory repair mechanisms are mediated through Toll-like receptors in response to activators produced by infections, hypoxic–ischemic damage, overwork and/or stress and elevated advanced glycation end products [14]. The associated coronary artery stenosis leads to decreased blood flow and reduced supply of nutrients and oxygen, leading to decreased ATP generation in blood vessels and heart muscle cells.

In the case of familial hypercholesterolemia, the supply of nutrients, particularly fats, to peripheral tissues is restricted from early age, due to defective or deficient LDL receptors. This leads to decreased ATP generation and cellular damage (Figure 3). Walter Hartenbach, former professor of pathology at München University, observed cellular damage in the artery well before fatty plaques (cholesterol accumulation) were formed [15].

In the case of statins, ATP generation is impaired by their inhibition of CoQ10 and of 'heme A' biosynthesis. Similar to the case of CHD and familial hypercholesterolemia (Figure 3), limited supply of ATP could be a major cause for heart muscle and coronary artery damage. The impact of statins on heart muscle will be
Selenoproteins using tRNA\textsubscript{sc} that is specific for selenocysteinyl failure through a common mechanism
Statin administration & selenium deficiency cause heart failure through a common mechanism
Selenoproteins include glutathione peroxidase, iodothyronine deiodinase, thioredoxin reductases and more than 10 other kinds of selenoproteins. When glutathione peroxidase synthesis is inhibited by statins, peroxidative stress is elevated, which is generally accepted as causative for atherogenesis, carcinogenesis and aging. Statins also lower the levels of antiperoxidative enzymes, such as superoxide dismutase and catalase, by unknown mechanisms (Figure 4).

In accordance with the mechanisms described above, glutathione peroxidase activity in erythrocytes was shown clinically to be inversely associated with CHD events and positively with event-free survival when patients with CHD were followed up for 5.4 years (Figure 6) [17].

Although not directly related to the topic of this article, selenoproteins are involved in several steps of glucose metabolism and insulin actions, providing a potential etiologic basis for statin-induced diabetes mellitus [18]. We presented an urgent proposal that statins are contraindicated in patients with diabetes mellitus [19].

**Statins inhibit vitamin K\textsubscript{2} synthesis & accelerate artery calcification**
Vitamin K\textsubscript{1} (VK\textsubscript{1}), rich in vegetable oils and vegetables, has one double bond at the phytanyl side chain. When ingested, its side chain is cleaved to form VK\textsubscript{3}, after which an isoprenyl residue with four double bonds is inserted into VK\textsubscript{3} to form VK\textsubscript{2} (menaquinone-4) (Figure 7). The enzymes synthesizing VK\textsubscript{2} from VK\textsubscript{3} are present in many tissues, including the brain, and statins inhibit the conversion of VK\textsubscript{3} to VK\textsubscript{2} by restricting the supply of the isoprenyl intermediate. VKs serve as cofactors for an enzyme catalyzing $\gamma$-carboxylation of glutamyl residues in proteins such as coagulation factors, osteocalcin and matrix Gla protein. VK\textsubscript{2} serves as the cofactor in the carboxylation of matrix Gla protein present in bone, blood vessel, lung, heart and kidney soft tissues. In

discussed later in this study. A recent example of the effect of statins on skeletal muscle has been evaluated (Figure 4) [16].

**Figure 4. Comparison of skeletal muscle properties in the leg between statin users and statin non-users.** As compared with non-users, statin users exhibited higher systolic blood pressure and elevated glycated hemoglobin (HbA1c) level. Levels of CoQ\textsubscript{10}, anti-peroxidative enzymes, uncoupling protein (UCP), Complex IV, and myosin were lower, oxidative phosphorylation ability was lower and glucose level in glucose tolerance test was higher [16].

* $p < 0.05$.  
AUC: Area under the curve; GSH: Glutathione; HC: Heavy chain; SBP: Systolic blood pressure; SOD: Superoxide dismutase.
Nakazato et al. evaluated coronary computed tomography angiography in 2413 patients on statins and 4260 patients not on statins. None of the subjects had any known coronary artery disease. Statin use was associated with a significant increase in the prevalence and extent of coronary plaques containing calcium [24].

In the case of end-stage kidney disease, the level of proteins induced via VK-absence (PIVKA-II) was elevated, the degree of carotid artery calcification was elevated, and coronary artery mortality and all-cause mortality were higher in those with lower matrix Gla protein levels [25]. Besides γ-carboxylation, VK2 is known to regulate gene expressions through the SXR receptor, and statins adverse effects through this pathway are expected to be revealed more extensively in the near future.

Thus, statins can stimulate atherogenesis and heart failure through the suppression of prenyl-intermediates.

**Clinical trials showing or suggesting that statins increased atherosclerotic disease & heart failure**

**Japan Lipid Intervention Trial**
This was the first large-scale intervention trial with a statin performed in Japan, and those with TC levels of ≥220 mg/dl were treated with a low-dose simvastatin for 6 years with no control group [26]. The horizontal axis in Figure 8 is plotted with TC levels after treatment. The mortality rates for cardiovascular disease, cerebrovascular disease, cancer and all causes were elevated along with decreasing TC levels from 220 mg/dl. The higher mortality rates in higher TC groups after treatment (Figure 8) could be due to the fact that this population included 12-fold greater proportion of familial hypercholesterolemia compared with that of general populations (0.2%). Although the authors of this report proposed to maintain TC levels below 240 mg/dl for the prevention of coronary events, we emphasized the risk of lowering TC levels below 220 mg/dl with statin [27].

**A follow-up study on US veterans with statins**
US veterans diagnosed with heart failure were treated with statins for 5 years and compared with those without statin treatment (Figure 9) [28]. The authors of this report concluded that ‘veterans who were not exposed to statin therapy at any time during the study period were 1.6-times more likely to suffer all-cause mortality’. However, a critical problem is...
associated with the statistics comparing statin users and statin nonusers. When statin users and nonusers were grouped, the former group should have TC (or LDL-C) levels higher than those in statin nonuser group. Particularly in aged group, inverse associations are often observed between TC levels and all-cause mortality [2]. Therefore, the statin user group should have characteristics leading to lower mortality at the start of the grouping, which is very likely to be reflected in the all-cause mortality shown in Figure 9. It is essential in this kind of cohort study to adjust background distribution of TC levels.

Incidence of diabetes mellitus was greater in the statin user group and appears to have increased along with the period of statin use (Figure 9), which is consistent with the observations that statins increase diabetes mellitus [18]. The pharmacological mechanisms of statins causing diabetes mellitus have been discussed in detail elsewhere [7].

More importantly, CHD mortality in the statin-user group was higher and appears to have increased along with the length of statin use when compared with the statin nonuser group (Figure 9). Among 72 years of age in average, no positive or even inverse association of CHD mortality with TC is expected [29], and the proportion of familial hypercholesterolemia is expected to be much less than in general population. Hence, we interpret the results (Figure 9) that statins increased CHD mortality through mechanisms as described in previous sections of this article. At least, we can point out that these results are not consistent with those of clinical trials performed in 1990s, in which a relative risk reduction of approximately 30% in CHD events is claimed (Figure 1, left).

**A large-scale follow-up study in Danes who were diagnosed with cancer**

Danes at ≥40 years of age and diagnosed with cancer were followed up for 15 years, and statin users and statin nonusers were compared [30]. In this large-scale, cohort study, the authors concluded that the cancer mortality and all-cause mortality were lower in the statin user group (Figure 10). However, the same criticism as described in the follow-up study on US veterans (Figure 9) applies to this conclusion, that is, background cholesterol levels need to be adjusted for between the groups of statin users and nonusers before making any conclusions.

Similar to the case in US veterans (Figure 9), the mortality from cardiovascular disease was higher in the statin user group and tended to increase dose dependently. We interpret the results to indicate that statins increased cardiovascular disease mortality in this population by the mechanisms described earlier in this article, or at least we can point out that these results are not consistent with those of clinical trials showing about a 30% decrease in CHD events (Figure 1, left).
Statin adverse effects on skeletal muscle are the most commonly reported side effects. Skeletal muscle weakness, muscle pain and skeletal muscle cell death with elevated creatinine kinase levels are a well-recognized phenomenon among prescribing physicians and patients alike. Statins have been demonstrated to decrease the concentration of mitochondria in muscle, oxidative phosphorylation capacity and skeletal muscle mitochondrial DNA levels [16,31,32]. In view of this obvious skeletal muscle toxicity, it would be naïve to assume that statins would not likewise negatively impact the much harder working heart muscle cells, which have exceedingly high ATP requirements. Indeed, in animal data, statins have been shown to increase mortality in cardiomyopathic hamsters [33] and to increase ischemia/reperfusion heart muscle damage in dogs [34–36].

Evidence for a causative role for statins in human heart failure

The first reported cases of statin-related heart failure were published in 1990 [37]. Five previously stable cardiomyopathic patients had a dramatic deterioration in myocardial function measurements and in clinical status shortly after beginning lovastatin. These patients returned to prestatin condition after stopping their statin therapy and doubling their supplemental CoQ10 from 100 to 200 mg/day.

In 2004, it was demonstrated that diastolic dysfunction developed in 10 of 14 healthy hyperlipidemic subjects after 3–6 months of atorvastatin at 20 mg/day [38]. Impairment in the ATP-dependent process of diastole is an early finding in congestive heart failure. In this study, the early diastolic dysfunction was asymptomatic and reversed to normal after 3 months of supplemental CoQ10 at 300 mg/day, while the patients continued to take their statin therapy. In contrast to this mild asymptomatic impairment in heart muscle function, in an ongoing study, patients who have been on statin treatment for an average of 6 years presented with overt and often permanent congestive heart failure.

In 2005, 50 consecutive patients presenting with severe statin side effects were followed up for a mean of 28 months [39]. In addition to symptoms of muscle pain and weakness, fatigue, dyspnea, peripheral neuropathy and memory loss, roughly one-fourth of these patients had evidence of congestive heart failure at the time of presentation. All 50 patients had their statin drug discontinued due to side effects and all were supplemented with an average of 240 mg of CoQ10 per day and followed up for 2 years. The patients’ chief complaints improved dramatically and 50% of those with heart failure showed significant improvement in heart muscle function. There were no adverse effects from statin drug discontinuation with no myocardial infarctions or strokes and no side effects from CoQ10 supplementation.

In 2008, a study in 29 patients with coronary artery disease found a significant increase in brain natriuretic peptide secondary to atorvastatin-induced plasma CoQ10 depletion [40] after a 3-month treatment with atorvastatin. Brain natriuretic peptide is a well-known marker for congestive heart failure.

Statin cardiomyopathy

Statin cardiomyopathy can be defined as an impairment in heart muscle function consequent to statin drug therapy and not explainable by any other underlying pathophysiology. Our current experience with statin cardiomyopathy indicates that it is not at all uncommon, with 130 cases identified during a 4-year period of time presenting to a solo cardiology practice. Although the impairment in heart muscle function, secondary to statin therapy, appears to be common after long-term (average 6 years) statin drug therapy, it is clear that it is not being recognized. In the words of Robertson Davies, ‘The eyes see only what the mind is prepared to comprehend’. Physicians in general are not aware that statins can cause heart failure and are clearly not recognizing it. Although vast majority of physicians readily recognize and diagnose heart failure in patients taking statins, the heart failure is almost always attributed to other non-statin-related factors, such as aging, hypertension and coronary artery disease. Furthermore, it is difficult to recognize any adverse drug effect when it is delayed by several years.

The mechanism for the impairment in heart muscle function appears to be related to impaired mitochondrial function, which in turn is related to statin depletion of CoQ10 [41], selenoproteins [42–44] and ‘heme A’ [45], all required for normal mitochondrial function. Statin-induced impairment in heart muscle function appears to be permanent, and even though
Persistent inflammation is considered a major risk factor for atherosclerosis and heart failure. Statins are known to suppress the prenylation of Rho protein and its downstream inflammatory cytokine production through NF-kB. Contrarily, statins decrease LDL levels leading to increased entry of lipopolysaccharide into cells and increased inflammatory cytokine production. Thus, the effect of statins on inflammation is likely to vary depending on the pathophysiological conditions.

Dolichol derived from prenyl-intermediates is essential for glycoprotein and glycolipid biosynthesis, and its suppression by statins would produce modified glycoproteins, for example, unglycosylated insulin receptor. Although the relationship between the statin suppression of dolichol synthesis and heart disease is yet to be clarified in detail, inborn mutation in dolichol kinase has been shown to be associated with dilated cardiomyopathy [47,48]. A vasodilatative molecule, nitric oxide (NO), is synthesized in endothelial cells, and statins inhibit the activation (prenylation) of Rho protein to up-regulate endothelial NO synthase and increase NO production [49]. On the other hand, statins inhibit inducible NO synthase gene expression in macrophages [50]. The impact of long-term endothelial NO synthase activation and inducible NO synthase inhibition on heart disease is not clear.

On the basis of these and other statin pleiotropic effects, statins seem to act as immune suppressive agents and may have beneficial effects on those who have excessive and/or life-threatening immune-inflammatory reactions, such as in transplantations [51]. However, immune suppression may be harmful in those who have no immune/inflammatory disease.

Many observational studies of statins on heart failure, retrospective or prospective studies, have been performed, some of which reported beneficial effects of statins on heart failure but others did not, as reviewed by Bonsu et al. [52]. Intervention trials generally provide more reliable conclusions compared with observational studies, and two large-scale, randomized controlled studies, GISSI-HF [53] and CORONA [54], reported no significant beneficial effects of statins in heart failure. In clinical fields, complex aspects of the etiology of heart failure (ischemic, idiopathic and inflammatory causes) should be taken into account rather than high cholesterol levels.

**Expert commentary**

Few cardiology specialists around the world have accepted that there is no clinical evidence for ‘the lower, the better hypothesis’. The majority of clinicians still appear to accept the results of meta-analysis of reports, including those published before 2004 when new penal regulations on the clinical trials came into effect in the EU, that is, statins are effective in lowering LDL-C levels and thereby preventing CHD incidence. Our group and others [2-4] only adopt the conclusions of papers reported after 2004 by scientists essentially free of conflict of interest that statins are ineffective in preventing CHD. Severe and often irreversible adverse effects of statins and their pharmacological mechanisms have been discussed in this study, indicating that the applicability of statins should be severely restricted. Clinicians should not rely on drug information provided by industry-funded trials, or should they trust study abstracts of clinical publications, which frequently do not provide the full picture and present many deceptions. Nondrug company-funded sources of information are likely to be much more useful and less biased.

**Five-year view**

Pharmacological evidence and clinical trial results support the interpretation that statins stimulate atherogenesis by suppressing
Statins stimulate atherosclerosis & heart failure


Papers of special note have been highlighted as:
- of considerable interest
  • of interest
  • of considerable interest

Key issues

- Pharmacological and biochemical studies reveal the mechanisms of statins to stimulate atherogenesis and heart failure, and some clinical studies support this interpretation.
- Statins are contraindicated in diabetics as statin administration did not prevent diabetics from CHD (ASPEN [55] and 4D study [56]), and statins worsen diabetic control [7]. Detailed mechanism of statin effects in diabetes has been published [7,19].
- ‘Informed consent’ of statins should include increased coronary artery disease, heart failure, carcinogenicity, teratogenicity and central and peripheral nervous disorders besides the known adverse effects.
- There have been several clinical papers published in which the abstracts are not consistent with the data in the text.

References

Papers of special note have been highlighted as:
- of interest
- of considerable interest


This book critically analyzed the available evidence underlying the so-called cholesterol hypothesis, leading to the conclusions that high blood cholesterol level is not a major causative factor for atherosclerosis among general populations over 40–50 years of age, the proportion of familial hypercholesterolemia in the study population is positively associated with relative risk of high cholesterol for coronary heart disease (CHD), and that high cholesterol is a predictor of low mortality rates from cancer and all causes. Instead, high dietary ω-6/ω-3 ratio and corresponding tissue ratio was proposed as the major risk factor associated with CHD.

3. Ravnkov U. Fat and cholesterol are good for you!. GB Publishing; Sweden: 2009

Following the pioneering book by this author ‘Cholesterol Myths’, this book emphasizes that there are no scientific lines of evidence for saturated fat and cholesterol causing atherosclerosis.


This book critically evaluated clinical papers claiming that statins are effective in lowering CHD events. The important roles of the new penal regulations on clinical trials, which came into effect in 2004 in the EU, were emphasized; dramatic decrease in effectiveness of statins in CHD was noted after the EU regulations.

5. Bollapragada SS, Norrie JD, Norman JE. Review of new regulations for the conduct of clinical trials of investigational medicinal products. BJOG 2007;114(18):917-21


As an extension of [2], this book from the Japan Society for Lipid Nutrition criticized the cholesterol guidelines for the prevention of atherosclerotic diseases, which had long been adopted by medical societies in Japan and also worldwide. New directions of lipid nutrition for the prevention of elderly-onset diseases were proposed.


11. Turunen M, Olson J, Dellner G. Metabolism and function of coenzyme Q.

17. Blankenberg S, Rupprecht HJ, Bickel C, For the first time, statins' adverse effects...

Based on observations on thousands of artery plaques, the author, former pathology professor at München University, emphasized that cholesterol is not a causative factor of atherosclerosis; pathological changes in artery tissues are observed well before fatty streaks in the artery wall are observed.

For the first time, statins' adverse effects on human skeletal muscle were evaluated biochemically. The reported changes in biochemical parameters caused by statin administration were substantiated.

A large-scale, long-term follow-up study on US nurses provided firm evidence that statins increase the onset of diabetes mellitus.


The first large-scale intervention trial with simvastatin performed mostly by members of the Japan Atherosclerosis Society. This article is important in understanding how the results are inconsistent with their cholesterol guidelines and were skewed by their interpretations.


A large-scale, cohort study of Danes, comparing statin users and statin non-users. This is a good example of the risk of simply reading the abstract without examining presented data; the possibility of statins causing cardiovascular diseases is obvious in the data presented.


Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004;94(10):1306-10

This is the first study to demonstrate that statins commonly produce diastolic dysfunction, a precursor to heart failure, in previously healthy subjects.

Langsjoen PH, Langsjoen JO, Langsjoen AM, et al. Treatment of statin adverse effects with supplemental Coenzyme


